Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 13/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | ORAI1 | Q96D31 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | PPP1CA | P62136 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | PDE2A | O00408 | 1/20 | 0.32 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3277360 | 0.83 | NR4A2 (0.35) | PTGESJAK2ORAI1ALDH1A1 | |
| SCHEMBL3276748 | 0.82 | SMN1; SMN2 (0.40) | PTGESJAK2HTTSMN1; SMN2LMNA | |
| SCHEMBL3276721 | 0.82 | BTK (0.34) | PTGESJAK2SMN1; SMN2LMNAORAI1 | |
| SCHEMBL3280715 | 0.77 | CCR1 (0.51) | PTGESJAK2HTTSMN1; SMN2LMNA | |
| SCHEMBL3277093 | 0.73 | PTGES (0.40) | PTGESJAK2HTTSMN1; SMN2LMNA | |
| SCHEMBL13385407 | 0.72 | CCR1 (0.44) | PTGESJAK2HTTSMN1; SMN2LMNA | |
| SCHEMBL13385404 | 0.72 | CYP1A1 (0.39) | PTGESALDH1A1 | |
| SCHEMBL13385412 | 0.71 | RAB9A (0.43) | SMN1; SMN2LMNAMAPK1ALDH1A1NPC1 | |
| SCHEMBL14384427 | 0.70 | PTGES (0.38) | PTGESJAK2HTTSMN1; SMN2LMNA | |
| SCHEMBL13385408 | 0.68 | PDE2A (0.36) | PTGESJAK2HTTSMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7695728-B2 | 2-substituted pyridines, processes for their preparation and their use for controlling harmful fungi | BASF AKTIENGESELLSCHAFT (DE) | 2010-04-13 | — | — | US | disclosed |
| EP-1761516-B1 | 2, 4, 5, 6-SUBSTITUTED PYRIMIDINES, METHOD FOR THE PRODUCTION AND USE THEREOF FOR COMBATING PARASITIC FUNGI | BASF AG (DE) | 2007-11-28 | — | — | EP | disclosed |
| US-20070259919-A1 | 2-Substituted Pyridines, Processes for their Preparation and Their Use for Controlling Harmful Fungi | BASF AKIENGESELLSCHAFT (DE) | 2007-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259919-A1 | 2-Substituted Pyridines, Processes for their Preparation and Their Use for Controlling Harmful Fungi | CYP4X1, CYCS, CYP2S1 | PTGES 1926/4885JAK2 2503/4885HTT 3132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.